Education
About Us
Working with TipRanks
Follow Us
Sionna Therapeutics, Inc. (SION)
NASDAQ:SION
SION Stock Chart & Stats
$34.71
--
Market closed
$34.71
--
Day’s Range― - ―
52-Week Range$7.26 - $43.20
Previous CloseN/A
VolumeN/A
Average Volume (3M)316.73K
Market Cap
$1.65B
Enterprise Value$512.36M
Total Cash (Recent Filing)$248.33M
Total Debt (Recent Filing)$8.97M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Mar 19, 2026EPS Estimate
-0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding44,628,788
10 Day Avg. Volume353,802
30 Day Avg. Volume316,734
Financial Highlights & Ratios
PEG Ratio-0.59
Price to Book (P/B)-6.74
Price to Sales (P/S)0.00
P/FCF Ratio-20.89
Enterprise Value/Market Cap0.31
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.07K
Enterprise Value/Ebitda-6.80
Forecast
1Y Price Target
$40.00Price Target Upside15.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressPhase 2a trial for '719 as an add-on to standard care in CF patients has been initiated, with data expected in mid-2026, indicating progress in clinical trials.
Financial StabilitySION has $325 million in cash, providing operational funding through 2028, ensuring financial stability for future developments.
Therapeutic PotentialNew preclinical data suggests '719 and '451 can restore F508del-CFTR half-life to normal levels, indicating strong therapeutic potential.
Bears Say
Clinical Performance ConcernsIf a drug has poor lung bioavailability or a patient's baseline disease is too advanced, it could perform less optimally in clinic than predicted by the assay.
Market Penetration ChallengesPatients stable on Trikafta are unlikely to be switched to a new drug, limiting the potential market for SION's new products.
Sionna Therapeutics, Inc. News
SION FAQ
What was Sionna Therapeutics, Inc.’s price range in the past 12 months?
Sionna Therapeutics, Inc. lowest stock price was $7.25 and its highest was $43.20 in the past 12 months.
What is Sionna Therapeutics, Inc.’s market cap?
Sionna Therapeutics, Inc.’s market cap is $1.65B.
When is Sionna Therapeutics, Inc.’s upcoming earnings report date?
Sionna Therapeutics, Inc.’s upcoming earnings report date is Mar 19, 2026 which is in 123 days.
How were Sionna Therapeutics, Inc.’s earnings last quarter?
Sionna Therapeutics, Inc. released its earnings results on Nov 05, 2025. The company reported -$0.46 earnings per share for the quarter, beating the consensus estimate of -$0.484 by $0.024.
Is Sionna Therapeutics, Inc. overvalued?
According to Wall Street analysts Sionna Therapeutics, Inc.’s price is currently Undervalued.
Does Sionna Therapeutics, Inc. pay dividends?
Sionna Therapeutics, Inc. does not currently pay dividends.
What is Sionna Therapeutics, Inc.’s EPS estimate?
Sionna Therapeutics, Inc.’s EPS estimate is -0.54.
How many shares outstanding does Sionna Therapeutics, Inc. have?
Sionna Therapeutics, Inc. has 44,628,788 shares outstanding.
What happened to Sionna Therapeutics, Inc.’s price movement after its last earnings report?
Sionna Therapeutics, Inc. reported an EPS of -$0.46 in its last earnings report, beating expectations of -$0.484. Following the earnings report the stock price went down -1.571%.
Which hedge fund is a major shareholder of Sionna Therapeutics, Inc.?
Currently, no hedge funds are holding shares in SION
Sionna Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.00 (15.24% Upside)
$40.00 (15.24% Upside)
Hedge Fund Trend
Increased
By 185.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $14.8M over
the Last 3 Months
the Last 3 Months
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
257.59%
Trailing 12-Months
Company Description
Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.
SION Stock 12 Month Forecast
Average Price Target
$40.00
▲(15.24% Upside)
Technical Analysis
Stoke Therapeutics
―
Vir Biotechnology
―
Immatics
―
Tango Therapeutics
―
Amylyx Pharmaceuticals Inc
―
Ownership Overview
53.96% Insiders
1.74% Mutual Funds
2.21% Other Institutional Investors
40.76% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---